Search clinical trials for: Anetumab Ravtansine

Total 474 results

ImmunityBio, Inc.

Unknown

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Pancreatic Cancer

United States
University of Rochester

Suspended

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

HER2-positive Breast Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Squamous Non-Small Cell Lung Cancer

Spain, Hungary, Serbia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Pancreatic Cancer

United States
Hoffmann-La Roche

Completed

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Breast Neoplasms

Canada, United States, France, Korea, Republic of, Spain, Belgium, Germany, Russian Federation, Taiwan, Ukraine
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Ashwin Somasundaram
EMD Serono; University of North Carolina, Chapel Hill

Completed

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Gastric Adenocarcinoma | Metastasis | Esophageal Adenocarcinoma | HER-2 Gene Amplification

United States
Universitair Ziekenhuis Brussel

Recruiting

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors (Luscid)

Solid Tumor | Non Small Cell Lung Cancer

Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditions

United States
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
Ludwig-Maximilians - University of Munich
Merck KGaA, Darmstadt, Germany; ClinAssess GmbH

Active, not recruiting

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Treatment Related Cancer

Germany
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Breast Cancer | HER2-positive Breast Cancer

United States
Population Health Research Institute

Recruiting

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction (SCHOLAR-2)

Heart Failure | Breast Cancer

Canada, Brazil, Russian Federation
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

Breast Cancer

Korea, Republic of, United States, Australia, China, Ukraine, Spain, United Kingdom, Turkey, Mexico, Brazil, Austria, Belgium, Denmark, Germany, Greece, Russian Federation, Taiwan, France, Kenya, New Zealand, Portugal, Thailand, Rom... and more
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Breast Cancer

United States, Italy, United Kingdom, Australia, Austria, Belgium, Brazil, Denmark, France, Guatemala, Korea, Republic of, Portugal, Spain, Turkey, Colombia, Canada, Czechia, Japan, Poland, Romania, Russian Federation, Switzerland, ... and more
Boehringer Ingelheim

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

Metastatic Breast Cancer

Korea, Republic of, United Kingdom, Australia, China, Croatia, Finland, France, Norway, Portugal, Slovenia, Canada, Italy, Spain, Colombia, Brazil, Poland, United States, Greece, Turkey, Russian Federation, Philippines
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Wilms Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Synovial Sarcoma | Pleuropulmonary Blastoma

United States
National Cancer Institute (NCI)

Terminated

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Breast Cancer

France, Italy, Spain, Hong Kong, United States, Canada, Mexico, Denmark, Germany, Portugal, Taiwan, Switzerland, Bulgaria, Korea, Republic of, Singapore, United Kingdom, Slovenia, Bosnia and Herzegovina, Russian Federation, Br... and more
M.D. Anderson Cancer Center

Active, not recruiting

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
ImmunityBio, Inc.

Terminated

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Pancreatic Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma Recurrent

United States
Pfizer

Completed

RN624 In Adult Patients With Chronic Low Back Pain

Low Back Pain

United States
Dana-Farber Cancer Institute
Pfizer

Active, not recruiting

Palbociclib After CDK and Endocrine Therapy (PACE)

Metastatic Breast Cancer

United States
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Neoplasm Metastasis

Australia, Korea, Republic of, China, United States, Portugal, Brazil, Singapore, Spain, United Kingdom, Belgium, Austria, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Me... and more
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast Cancer

United States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
Otto Metzger, MD
Genentech, Inc.

Active, not recruiting

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Federation Francophone de Cancerologie Digestive

Active, not recruiting

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)

Metastatic Colorectal Cancer | MSI

France
Carey Anders, M.D.
Seagen Inc.

Recruiting

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (BRIDGET)

Advanced Breast Cancer | Brain Metastases | Human Epidermal Growth Factor 2 Positive Carcinoma of Breast

United States
Enliven Therapeutics

Recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

HER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 Amplification

Spain, United States, Korea, Republic of, Taiwan, Italy, Australia, France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Non Hodgkin Lymphoma
Gilead Sciences
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (TROPHY U-01)

Metastatic Urothelial Cancer

Italy, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
M.D. Anderson Cancer Center
Genentech, Inc.; Seagen Inc.

Recruiting

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Metastatic Solid Tumor | Brain Metastases

United States
University College, London
Hoffmann-La Roche

Active, not recruiting

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)

Non-small Cell Lung Cancer

United Kingdom
ImmunityBio, Inc.

Withdrawn

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Chordoma | Unresectable Malignant Neoplasm

United States
Karolinska Institutet
Bristol-Myers Squibb; Sanofi; Swedish Heart Lung Foundation

Completed

Irbesartan and Atenolol in Hypertensive Heart Disease (SILVHIA)

Hypertension

Sweden
Emory University
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
Fate Therapeutics

Terminated

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Gruppo Oncologico del Nord-Ovest

Active, not recruiting

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC)

Metastatic Colorectal Cancer

Italy
University of Leipzig
Abbott Medical Devices; Leipzig Heart Institute GmbH; Zentrum für Klinische Studien...

Completed

Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease (CAT-PVC)

Heart Diseases | Cardiomyopathies | Ventricular Premature Complexes

Germany
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan

Search clinical trials for: Anetumab Ravtansine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations